{"log_id": 3132141798707592595, "direction": 0, "words_result_num": 40, "words_result": [{"probability": {"variance": 3e-06, "average": 0.998871, "min": 0.991364}, "location": {"width": 735, "top": 128, "height": 32, "left": 168}, "words": "在两项随机对照研究中评价了本品单药用于晚期胃癌的疗效和安全性"}, {"probability": {"variance": 5e-06, "average": 0.998997, "min": 0.990031}, "location": {"width": 919, "top": 177, "height": 32, "left": 191}, "words": "项多中心、随机、双盲、安慰剂平行对照的Ⅲ期临床研究对阿帕替尼治疗晚期胃癌的有"}, {"probability": {"variance": 1e-06, "average": 0.999218, "min": 0.995276}, "location": {"width": 980, "top": 225, "height": 31, "left": 119}, "words": "效性和安全性进行了评价。研究入组了267例既往接受过二线治疗后失败(治疗失败的定义"}, {"probability": {"variance": 0.000544, "average": 0.994011, "min": 0.8547}, "location": {"width": 992, "top": 273, "height": 32, "left": 119}, "words": "毒副作用不可耐受、治疗过程中疾病进展或治疗结束后复发)的晚期胃癌患者,包括胃-食管"}, {"probability": {"variance": 0.00012, "average": 0.995834, "min": 0.934551}, "location": {"width": 993, "top": 322, "height": 31, "left": 118}, "words": "结合部腺癌患者。接受阿帕替尼治疗患者中位年龄58岁,75%为男性;27%患者ECOG评分"}, {"probability": {"variance": 0.000258, "average": 0.994797, "min": 0.905903}, "location": {"width": 992, "top": 371, "height": 30, "left": 119}, "words": "为0,73%患者ECOG评分为1;约60%进行过根治术治疗,约22%进行了胃全切手术,35%"}, {"probability": {"variance": 8.7e-05, "average": 0.996672, "min": 0.960732}, "location": {"width": 993, "top": 419, "height": 30, "left": 117}, "words": "进行了胃大切手术;68%原发灶为胃癌,22%为胃食管结合部腺癌;21%患者转移灶累积器官"}, {"probability": {"variance": 0.002092, "average": 0.989419, "min": 0.727025}, "location": {"width": 995, "top": 469, "height": 29, "left": 117}, "words": "数超过2个,56%患者存在肝转移,92%患者临床分期为IV期;66%患者既往接受过至少2"}, {"probability": {"variance": 1.3e-05, "average": 0.998668, "min": 0.979076}, "location": {"width": 991, "top": 515, "height": 31, "left": 118}, "words": "种系统化疗,一线化疗基础用药包括氟尿嘧啶类、铂类、紫杉醇类、阿霉素类,二线化疗主要"}, {"probability": {"variance": 2e-05, "average": 0.998436, "min": 0.971769}, "location": {"width": 990, "top": 563, "height": 31, "left": 119}, "words": "以伊立替康为基础治疗的方案。试验组与安慰剂组受试者基线特征和人口学数据均衡可比。患"}, {"probability": {"variance": 1.2e-05, "average": 0.997588, "min": 0.985147}, "location": {"width": 993, "top": 610, "height": 31, "left": 118}, "words": "者按2:1随机接受阿帕替尼片850mg每日1次(n=176)或安慰剂每日一次(n=91),28天"}, {"probability": {"variance": 7e-05, "average": 0.997743, "min": 0.944316}, "location": {"width": 991, "top": 658, "height": 30, "left": 118}, "words": "为一个周期。试验组患者平均接受治疗周期数为2.9,72%的受试者接受了2个周期或以上的"}, {"probability": {"variance": 0, "average": 0.999892, "min": 0.99985}, "location": {"width": 48, "top": 709, "height": 27, "left": 118}, "words": "治疗"}, {"probability": {"variance": 0.002434, "average": 0.985025, "min": 0.714393}, "location": {"width": 946, "top": 754, "height": 31, "left": 165}, "words": "研究主要疗效评价指标为总生存期(OS),次要疗效指标包括无进展生存期(PFS)、疾"}, {"probability": {"variance": 5.4e-05, "average": 0.996266, "min": 0.967132}, "location": {"width": 993, "top": 800, "height": 31, "left": 117}, "words": "疾病控制率(DCR)和客观缓解率(ORR)。试验组中位总生存期较安慰剂组延长,降低死亡"}, {"probability": {"variance": 0.001208, "average": 0.990967, "min": 0.774062}, "location": {"width": 995, "top": 847, "height": 30, "left": 116}, "words": "风险约30%。次要终点PFS、DCR亦高于安慰剂组,总体上未引起晚期胃癌特异症状或健康"}, {"probability": {"variance": 2.9e-05, "average": 0.998213, "min": 0.969917}, "location": {"width": 735, "top": 893, "height": 32, "left": 117}, "words": "相关生活质量的恶化。表3列出了主要疗效结果,图1为生存曲线图"}, {"probability": {"variance": 0.00077, "average": 0.991239, "min": 0.849033}, "location": {"width": 654, "top": 947, "height": 27, "left": 283}, "words": "表3.阿帕替尼治疗胃癌的I期临床研究的主要有效性结果(FAS集)"}, {"probability": {"variance": 0, "average": 0.999582, "min": 0.999313}, "location": {"width": 47, "top": 992, "height": 26, "left": 359}, "words": "指标"}, {"probability": {"variance": 9.2e-05, "average": 0.992077, "min": 0.966499}, "location": {"width": 139, "top": 992, "height": 25, "left": 601}, "words": "试验组(N=176)"}, {"probability": {"variance": 0.009069, "average": 0.959042, "min": 0.67523}, "location": {"width": 151, "top": 992, "height": 27, "left": 829}, "words": "安慰剂组(N=91)"}, {"probability": {"variance": 0.030967, "average": 0.888996, "min": 0.538974}, "location": {"width": 150, "top": 1037, "height": 26, "left": 217}, "words": "总生存期(OS)"}, {"probability": {"variance": 0.019006, "average": 0.931377, "min": 0.573452}, "location": {"width": 192, "top": 1077, "height": 25, "left": 249}, "words": "中位数(mOs,月)"}, {"probability": {"variance": 0, "average": 0.999063, "min": 0.999063}, "location": {"width": 14, "top": 1081, "height": 19, "left": 673}, "words": "5"}, {"probability": {"variance": 0.000687, "average": 0.979333, "min": 0.924682}, "location": {"width": 106, "top": 1120, "height": 23, "left": 250}, "words": " HR(95% CI"}, {"probability": {"variance": 0.01135, "average": 0.952847, "min": 0.628417}, "location": {"width": 264, "top": 1118, "height": 28, "left": 691}, "words": "0709(0.537,0.937)"}, {"probability": {"variance": 0.005414, "average": 0.94815, "min": 0.745327}, "location": {"width": 201, "top": 1159, "height": 27, "left": 220}, "words": "无进展生存期(PFS)"}, {"probability": {"variance": 0.007976, "average": 0.964474, "min": 0.683083}, "location": {"width": 201, "top": 1201, "height": 26, "left": 249}, "words": "中位数(mPFS,月)"}, {"probability": {"variance": 0.000196, "average": 0.98884, "min": 0.969047}, "location": {"width": 29, "top": 1203, "height": 20, "left": 656}, "words": "2.6"}, {"probability": {"variance": 0, "average": 0.997199, "min": 0.997199}, "location": {"width": 18, "top": 1203, "height": 20, "left": 903}, "words": "8"}, {"probability": {"variance": 0.022612, "average": 0.903031, "min": 0.564034}, "location": {"width": 110, "top": 1246, "height": 22, "left": 250}, "words": "HR(95%℃I)"}, {"probability": {"variance": 0.000484, "average": 0.988688, "min": 0.906045}, "location": {"width": 170, "top": 1245, "height": 21, "left": 694}, "words": "0.444(0.331,0.595)"}, {"probability": {"variance": 0.005732, "average": 0.946952, "min": 0.784472}, "location": {"width": 218, "top": 1286, "height": 26, "left": 217}, "words": "客观缓解率(CR+PR)"}, {"probability": {"variance": 0.000174, "average": 0.990579, "min": 0.964876}, "location": {"width": 60, "top": 1287, "height": 21, "left": 641}, "words": "2.84%"}, {"probability": {"variance": 0, "average": 0.970174, "min": 0.970174}, "location": {"width": 17, "top": 1288, "height": 19, "left": 895}, "words": "0"}, {"probability": {"variance": 0.006864, "average": 0.955697, "min": 0.676851}, "location": {"width": 258, "top": 1327, "height": 27, "left": 218}, "words": "临床获益率(CR+PR+SD)"}, {"probability": {"variance": 0.002692, "average": 0.963933, "min": 0.865609}, "location": {"width": 60, "top": 1329, "height": 20, "left": 644}, "words": "42.05%"}, {"probability": {"variance": 0.000651, "average": 0.986061, "min": 0.935092}, "location": {"width": 59, "top": 1329, "height": 20, "left": 875}, "words": "8.79%"}, {"probability": {"variance": 0.000678, "average": 0.98685, "min": 0.851881}, "location": {"width": 988, "top": 1373, "height": 33, "left": 116}, "words": "注:FAS:全分析集;mOS:中位总生存期;mPFS:中位无进展生存期;CR:完全缓解;PR:部分缓解"}, {"probability": {"variance": 0.001208, "average": 0.982763, "min": 0.898086}, "location": {"width": 134, "top": 1432, "height": 26, "left": 160}, "words": "SD:疾病稳定"}], "language": 3}